Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of NTLA-2002 in previously treated hereditary angioedema participants
NL-OMON59872Phase 2Recruiting
- Sponsor
- Intellia Therapeutics
- Start
- May 2024
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lonvoguran in hereditary angioedema (HAE), sponsored by Intellia Therapeutics. Primary endpoints: Incidence of treatment-related adverse events, Incidence of treatment-related serious adverse events and 1 more. Started May 2024; status: recruiting.
02
Drugs
lonvoguran
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON59872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59872.